Allogene Therapeutics (ALLO) Receivables - Accured (2018 - 2019)

Allogene Therapeutics (ALLO) posted Receivables - Accured of $2.3 million for Q3 2019, down 28.86% sequentially from $3.3 million in Q2 2019.

Allogene Therapeutics (ALLO) Receivables - Accured (2018 - 2019) Analysis & Trends

Allogene Therapeutics has reported Receivables - Accured for 2 years, with the latest figure at $2.3 million in Q3 2019.

Quarterly Receivables - Accured changed N/A year-over-year to $2.3 million in Q3 2019, while the trailing twelve-month figure through Sep 2019 was $2.3 million (changed N/A YoY) and the FY2018 annual result came in at $3.1 million, changed N/A from the prior year.
Receivables - Accured retreated to $2.3 million in Q3 2019 per ALLO's latest filing, from $3.3 million in the prior quarter.
Over five years, Receivables - Accured peaked at $3.4 million in Q1 2019 and troughed at $2.3 million in Q3 2019.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Acc. Int. Receivables (Qtr)
1	Vertex Pharmaceuticals	128.13 Bn	120.28 Bn	2.84 Bn	-
2	Regeneron Pharmaceuticals	112.33 Bn	104.33 Bn	3.93 Bn	-
3	Argenx Se	53.24 Bn	48.05 Bn	1.41 Bn	-
4	Revolution Medicines	43.64 Bn	43.64 Bn	-	-
5	BeOne Medicines	39.27 Bn	34.17 Bn	1.53 Bn	-
6	MindWalk Holdings	35.32 Bn	35.31 Bn	1.82 Bn	-
7	Royalty Pharma	33.72 Bn	35.84 Bn	-	-
8	Alnylam Pharmaceuticals	30.58 Bn	27.27 Bn	992.69 Mn	-
9	Insmed	27.01 Bn	25.85 Bn	358.27 Mn	-
10	Allogene Therapeutics	707.96 Mn	707.96 Mn	-	-

Download Data